Vladimir P. Torchilin
Affiliated Faculty,
Chemical Engineering
University Distinguished Professor and Director,
Pharmaceutical Sciences
Contact
- v.torchilin@northeastern.edu
- 360 Huntington Ave
Boston, MA 02115
Office
- 140 The Fenway, Room 211/214
- 617.373.3206
Research Focus
Drug delivery and targeting; Drug carriers; Pharmaceutical biotechnology; Experimental cancer immunology; Nanomedicine; Pharmaceutical carriers; Liposomes and micelles
Honors & Awards
- 1982 Lenin Prize of the USSR in Science and Technology (the highest scientific award in the former USSR)
- 2002 Fellow, American Institute for Medical and Biological Engineering
- 2002 Member, European Academy of Sciences
- 2003 Fellow, American Association of Pharmaceutical Scientists (AAPS)
- 2003 ATOMS Research Excellence in Mentorship Award, National Institute of General Medical Sciences
- 2005 President, Controlled Release Society
- 2005 Research Achievements Award in Pharmaceutics and Drug Delivery, AAPS
- 2005 The Joy Goodwin Lecturer, Auburn University
- 2006 2006 CRS-Baxter Healthcare Outstanding Parenteral Drug Delivery Award
- 2006 The Massachusetts Technology Transfer Center 2006 Investigation Award
- 2007 Research Achievements Award from the World Pharmaceutical Congress, Amsterdam
- 2008 Prestige Lectureship, University of Montreal
- 2008 Horizons in Nanotechnology Lectureship, Emory University
- 2009 University of North Carolina-Eisai Distinguished Lectureship in Drug Delivery
- 2009 The Meritorious Paper AAPS Journal 2008 Award
- 2009 2009 International Journal of Nanomedicine Distinguished Scientist Award
- 2010 Avis Distinguished Visiting Professor Lectureship, University of Tennessee, Memphis
- 2010 Founders Award, Controlled Release Society
- 2012 Alec Bangham Life Achievement Award
- 2013 Journal of Drug Targeting Life Time Achievement Award
- 2013 Blaise Pascal Medal in Biomedicine from the European Academy of Sciences
- 2015 Chair, XX International Symposium on Microencapsulation, Boston
- 2015 European Journal of Pharmaceutics and Biopharmaceutics best paper award for 2014
- 2016 International Chair of Therapeutic Innovation, LabEx LERMIT, France
- 2017 Outstanding Excellence Award from Pharmaceutica 2017, London, UK
- 2017 Albert Nelson Marquis Lifetime Achievement Award
- 2018 President, BIONANOTOX, Greece
- 2018 Conference Chair, Material Science-2018, Amsterdam, The Netherlands
- 2019 Highly Cited Researcher from Thomson Reuters
Research Overview
Drug delivery and targeting; Drug carriers; Pharmaceutical biotechnology; Experimental cancer immunology; Nanomedicine; Pharmaceutical carriers; Liposomes and micelles
Dendrimers as pharmaceutical carriers; Co-delivery of siRNA and chemotherapeutics for multidrug resistant cancer; Hypoxia-mediated drug delivery
Center for Pharmaceutical Biotechnology and Nanomedicine
The Center for Pharmaceutical Biotechnology and Nanomedicine was created to perform studies at the juncture of two fast-growing scientific areas: biotechnology and nanomedicine. The Center is directed by Dr. Vladimir Torchilin, University Distinguished Professor of Pharmaceutical Sciences.
This Center aims to host and coordinate research in pharmaceutical nanocarriers, controlled drug and gene delivery, drug targeting, intracellular targeting, experimental medical imaging, and cancer immunology, and train young researches in these areas.
Research Centers and Institutes
- Director, Center for Pharmaceutical Biotechnology and Nanomedicine
Department Research Areas
Selected Publications
- Filipczak N, Jaromin A, Piwoni A, Mahmud M, Sarisozen C, Torchilin V, Gubernator J. A Triple Co-Delivery Liposomal Carrier That Enhances Apoptosis via an Intrinsic Pathway in Melanoma Cells. Cancers (Basel). 2019 Dec 9;11(12)
- Zhang X, Pan J, Yao M, Palmerston Mendes L, Sarisozen C, Mao S, Torchilin VP, Charge reversible hyaluronic acid-modified dendrimer-based nanoparticles for siMDR-1 and doxorubicin co-delivery. Eur. J. Pharm. Biopharm. 154, 43-49, 2020.
- Khan MM, Madni A, Filipczak N, Pan J, Rehman M, Rai N, Attia SA, Torchilin VP, Folate targeted lipid chitosan hybrid nanoparticles for enhanced anti-tumor efficacy. Nanomedicine. 2020; 28:102228.
- Pan J, Attia SA, Subhan MA, Filipczak N, Mendes LP, Li X, Kishan Yalamarty SS, Torchilin VP, Monoclonal Antibody 2C5-Modified Mixed Dendrimer Micelles for Tumor-Targeted Codelivery of Chemotherapeutics and siRNA. Mol. Pharm. 17, 1638-1647, 2020.
- Joshi U, Filipczak N, Khan MM, Attia SA, Torchilin V, Hypoxia-sensitive micellar nanoparticles for co-delivery of siRNA and chemotherapeutics to overcome multi-drug resistance in tumor cells. Int J Pharm. 2020; 590:119915.
- Mendes LP, Rostamizadeh K, Gollomp K, Myerson JW, Marcos-Contreras OA, Zamora M, Luther E, Brenner JS, Filipczak N, Li X, Torchilin VP, Monoclonal antibody 2C5 specifically targets neutrophil extracellular traps. MAbs. 2020; 12(1):1850394
Jan 31, 2025
2024 Stanford University Annual Assessment of Author Citations
The following COE professors are among the top scientists worldwide selected by Stanford University representing the top 2% of the most-cited scientists with single-year impact in various disciplines. The selection is based on the top 100,000 by c-score (with and without self-citations) or a percentile rank of 2% or above. The list below includes those who published a paper in 2024 or later.
Nov 02, 2022
2022 Stanford University Annual Assessment of Author Citations
A group of COE professors are among the top scientists worldwide selected by Stanford University representing the top 2% of the most-cited scientists with single-year impact in various disciplines. The selection is based on the top 100,000 by c-score (with and without self-citations) or a percentile rank of 2% or above.